Vanguard Group Inc Lexaria Bioscience Corp. Transaction History

Vanguard Group Inc

$6.44 Trillion
Q3 2025

A detailed history of Vanguard Group Inc transactions in Lexaria Bioscience Corp. stock. As of the latest transaction made, Vanguard Group Inc holds 258,816 shares of LEXX stock, worth $274,344. This represents 0.0% of its overall portfolio holdings.

Number of Shares

258,816

Previous 133,554 93.79%

Holding current value

$274,344

Previous $116,000 111.21%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 07, 2025	BUY	$0.79 - $1.53 $98,956 - $191,650	125,262 Added 93.79%	258,816 $245,000
Q2 2025 Aug 11, 2025	BUY	$0.85 - $1.69 $4,830 - $9,604	5,683 Added 4.44%	133,554 $116,000
Q1 2025 May 09, 2025	BUY	$1.22 - $2.29 $534 - $1,003	438 Added 0.34%	127,871 $218,000
Q4 2024 Feb 11, 2025	BUY	$2.01 - $3.3 $37,006 - $60,756	18,411 Added 16.89%	127,433 $268,000
Q3 2024 Nov 13, 2024	BUY	$2.58 - $4.09 $39,824 - $63,133	15,436 Added 16.49%	109,022 $332,000

Q2 2024 Aug 13, 2024	BUY	$1.99 - $4.0 $16,775 - $33,720	8,430 Added 9.9%	93,586 $260,000
Q1 2024 May 10, 2024	BUY	$1.29 - $6.25 $50,200 - $243,218	38,915 Added 84.16%	85,156 $309,000
Q4 2023 Feb 14, 2024	BUY	$0.92 - $1.69 $11,879 - $21,821	12,912 Added 38.74%	46,241 $57,000
Q4 2022 Feb 10, 2023	BUY	$1.95 - $2.98 $321 - $491	165 Added 0.5%	33,329 $81,000
Q3 2022 Nov 14, 2022	SELL	$0.74 - $3.28 $708 - $3,142	-958 Reduced 2.81%	33,164 $81,000
Q4 2021 Feb 14, 2022	BUY	$3.87 - $6.9 $12,724 - $22,687	3,288 Added 10.66%	34,122 $138,000
Q3 2021 Nov 12, 2021	BUY	$5.39 - $8.44 $26,184 - $41,001	4,858 Added 18.7%	30,834 $193,000
Q2 2021 Aug 13, 2021	BUY	$4.61 - $7.02 $119,749 - $182,351	25,976 New	25,976 $182,000

Others Institutions Holding LEXX

# of Institutions

Shares Held

1.76M

Call Options Held

Put Options Held

View Full List

About Lexaria Bioscience Corp.

Ticker LEXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,951,000
Market Cap $6.31M
Description
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x ...

More about LEXX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Lexaria Bioscience Corp. Transaction History